ISC-hpNSC is under clinical development by International Stem Cell and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ISC-hpNSC’s likelihood of approval (LoA) and phase transition for Parkinson’s Disease took place on 02 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ISC-hpNSC Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ISC-hpNSC overview

ISC-hpNSC is under development for the treatment of Parkinson’s disease, ischemic stroke and traumatic brain injury. The therapeutic candidate is a stem cell therapy which is injected intracerebrally to the striatum and substantia nigra of patients with Parkinson's disease (PD). The therapeutic candidate is developed through a stem cell technology known as parthenogenesis.Parthenogenesis helps in the development of a class of stem cells, human parthenogenesis stem cells (hpSCs) that have the best characteristics of each of the other classes of stem cells.

International Stem Cell overview

International Stem Cell (ISCC) is a clinical stage biotechnology company that develops stem cell technology solutions. The company develops parthenogenesis, a stem cell technology that improves the field of regenerative medicine. It provides stem cells such as embryonic stem cells, adult stem cells, induced pluripotent stem cells, and parthenogenetic stem cells. ISCC uses human parthenogenetic stem cells (hpSC) to treat severe diseases of the central nervous system, joints and liver. The company has also developed a new class of pluripotent human stem cells derived from unfertilized eggs. It also conducts clinical trials for the treatment of moderate to severe Parkinson’s disease. ISCC is headquartered in San Diego, California, the US.

Quick View ISC-hpNSC LOA Data

Report Segments
  • Innovator
Drug Name
  • ISC-hpNSC
Administration Pathway
  • Intracerebral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.